✦ LIBER ✦

General Principles and Pharmacology of Biologics in Inflammatory Bowel Disease

✍ Scribed by Kozuch, Patricia L.; Hanauer, Stephen B.

Book ID: 122804191
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 288 KB
Volume: 35
Category: Article
ISSN: 0889-8553
DOI: 10.1016/j.gtc.2006.09.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety of biologics in inflammatory bowe

Safety of biologics in inflammatory bowel disease

✍ Wojciech Blonski; Gary R. Lichtenstein 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 602 KB

General principles of medical therapy of

General principles of medical therapy of inflammatory bowel disease

✍ Friedman, Sonia 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 261 KB

Use of biologics in inflammatory bowel d

Use of biologics in inflammatory bowel disease patients with cirrhosis

✍ Tanvi Dhere 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 40 KB 👁 2 views

Therapeutic drug monitoring of biologics

Therapeutic drug monitoring of biologics for inflammatory bowel disease

✍ Jean-Frédéric Colombel; Brian G. Feagan; William J. Sandborn; Gert Van Assche; A 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 434 KB 👁 1 views

## Background: Although tumor necrosis factor (tnf) antagonists are effective for the treatment of crohn's disease and ulcerative colitis, lack and loss of clinical response is a clinical challenge. accordingly, the use of therapeutic drug monitoring has been proposed as a means to optimize treatme

Immunology of Inflammatory Bowel Disease

Immunology of Inflammatory Bowel Disease and Molecular Targets for Biologics

✍ Dave, Maneesh; Papadakis, Konstantinos A.; Faubion, William A. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 874 KB

Stopping immunomodulators and biologics

Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission

✍ Kofi Clarke; Miguel Regueiro 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

The emergence of biologic response modifiers and earlier use of immunomodulators for inflammatory bowel disease (IBD) patients have improved outcomes. Durable remissions have been achieved in many IBD patients on these treatments, but the duration of treatment and identifying which patients may stop